Mon panier

CD55

CD55 Informations sur la molécule

Nom anglaisComplement decay-accelerating factorNombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleDAF,Complement decay-accelerating factor,CD55,CD55 Molecule (Cromer Blood Group),CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group),CD55 Antigen,CR,Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System),Cromer Blood Group Antigen,CHAPLE,CROM,TC,CD55 Antigens
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisComplement decay-accelerating factor
Alias de la cibleDAF,Complement decay-accelerating factor,CD55,CD55 Molecule (Cromer Blood Group),CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group),CD55 Antigen,CR,Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System),Cromer Blood Group Antigen,CHAPLE,CROM,TC,CD55 Antigens
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

CD55 Liste de produits

  • Attribut

    Protein (2)

  • Bibliothèque de produits

    En ligne (2)

  • Espèces

    Human (2)

  • Étiquette

    His Tag (1)His Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (1)Biotin-labeled (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
CD5-H5225
Human
HEK293
Human CD55 / DAF Protein, His Tag, low endotoxin
Ajouter au panier
CD5-H82E4
Human
HEK293
Biotinylated Human CD55 / DAF Protein, His,Avitag™ (MALS verified)
Ajouter au panier
Quantité totale2
  • 1

CD55Contexte de la molécule

CD55 is also known as DAF or decay­accelerating factor, is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. CD55 /DAF is a 70 kDa membrane protein that regulates the complement system on the cell surface. It prevents the assembly of the C3bBb complex (the C3-convertase of the alternative pathway) or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex. This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system. CD55 is known to bind CD97 via the first SCR. It also binds physiologically­generated C3 convertases with its second and third SCRs. Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells. Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection.

CD55Alias de la molécule

CD55,DAF,CR,CROM,TC

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
GebasaxturevV-937; CVA-21Phase 2 ClinicalViralytics LtdBreast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Prostatic Neoplasms; Urinary Bladder Neoplasms
Details
PAT-SC1SC-1; PAT-SC1; PAT-SC-1Phase 2 ClinicalOncomab GmbhStomach Neoplasms
Details
Recombinant coxsackievirus B3Phase 1 ClinicalWuhan Boweid Biotechnology Co LtdNeoplasms
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques